A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Plozalizumab (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 26 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment due to business decision; No Safety or Efficacy Concerns
- 26 Jul 2016 Status changed from recruiting to discontinued.
- 19 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.